{"analyses":[{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.48","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7733","paramType":"Hazard Ratio (HR)","paramValue":"1.05","statisticalComment":"Strata: intolerance to imatinib treatment","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% confidence interval (CI) was not estimable due to fewer number of participants with events","groupId":"OG000","lowerLimit":"29.3","upperLimit":"NA","value":"34.0"},{"comment":"Upper limit of 95% confidence interval (CI) was not estimable due to fewer number of participants with events","groupId":"OG001","lowerLimit":"29.4","upperLimit":"NA","value":"31.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"OG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"The KIT Exon 11 Intent to Treat (ITT) Population is defined as all patients who are designated as having a mutation in KIT Exon 11 at the time of randomization. Patients in this population will be analyzed according to the treatment they were scheduled to receive.","reportingStatus":"POSTED","timeFrame":"From date of randomization until death due to any cause (up to 3.33 years)","title":"Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population","type":"SECONDARY","unitOfMeasure":"months"}